ArticleDiabetes, obesity & metabolism2022

Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.

Joanne Webb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.